

# ForPatients

by Roche

Influenza

## Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

**Trial Status**  
Completed

**Trial Runs In**  
28 Countries

**Trial Identifier**  
NCT03684044 2018-001416-30  
CP40617

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03684044 2018-001416-30 CP40617**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥ 12 Years

**Healthy Volunteers**  
No

---